# Scopolamine Challenge Study

> **NCT01213355** · PHASE1 · COMPLETED · sponsor: **Pfizer** · enrollment: 38 (actual)

## Conditions studied

- Healthy

## Interventions

- **DRUG:** Placebo
- **DRUG:** Scopolamine
- **DRUG:** PF-05212377
- **DRUG:** Scopolamine
- **DRUG:** PF-05212377
- **DRUG:** scopolamine
- **DRUG:** PF-05212377
- **DRUG:** scopolamine
- **DRUG:** Donepezil
- **DRUG:** Scopolamine

## Key facts

- **NCT ID:** NCT01213355
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-04
- **Primary completion:** 2011-08
- **Final completion:** 2011-08
- **Target enrollment:** 38 (ACTUAL)
- **Last updated:** 2018-11-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01213355

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01213355, "Scopolamine Challenge Study". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01213355. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*